Beamtree Holdings Limited (ASX: BMT)
ASX Announcement

Sydney, 26 November 2026

Annual General Meeting – Chair and CEO Addresses

Beamtree Holdings Limited (**ASX: BMT**) ("**Beamtree**" or the "**Company**") advises that the 2026 Annual General Meeting (AGM) will be held today, 26 November 2026 at 10:00 am (AEDT) at Level 5, 126 Phillip Street, Sydney NSW 2000 and as a virtual meeting.

Attached are the Chair and CEO Addresses which will be delivered at the AGM today.

-ENDS-

This announcement has been authorised for release by the Board of Beamtree.

For further information, please email investor@beamtree.com.au

Beamtree

Beamtree Holdings Limited (ASX: BMT)
ASX Announcement

Sydney, 26 November 2026

Chair's Address to the AGM

Introduction

Good morning, ladies and gentlemen.

Welcome to the 2026 Annual General Meeting for Beamtree Holdings Limited.

It is 10am, we have a quorum present, and I declare the meeting open.

Before we start, I would like to acknowledge this AGM is being held on the traditional lands of the Gadigal people. I pay my respect to their elders past and present.

I am Emma Gray, Chairman of Beamtree, and I am chairing the meeting today.

I am also joined by my fellow Directors: Martin Bowles, who is in the room; Mike Hill, who is attending remotely; and Stuart MacDonald and Andy Hardy, who have sent their apologies. We are delighted to welcome Martin, our newest Non-Executive Director, to his first Beamtree AGM.

Next to me is our Chief Executive Officer, Gareth Pye, and our interim CFO, Neil Thompson, is also in the room.

On behalf of the Board, I would characterise 2026 as a year where we delivered significant innovation for our customers, strengthening our core domestic market and affirming our overseas investments.

This has been a pivotal year for Beamtree. We have been through a great deal of change, and the Board is confident in the team and the path forward.

The strategic review

In February the Board started a review of the business. I stepped in as Executive Chair to lead it, handing day-to-day leadership back to our new CEO in early August, and the review closed at the end of that month. We asked three questions: where are we strong, what is holding us back, and what has to change. Five decisions came out of it.

- **We focused the portfolio.** We are investing where customers value us most and where we can earn a margin: RippleDown in pathology, our integrated hospital coding suite (PICQ, PICQ Audit and RISQ), and our data platforms.
- **We exited what did not fit.** We closed the Ability Roundtable and Wellness Roundtable, and are winding down the Ainsoff Deterioration Index with affected customers.
- **We reset costs to match revenue.** Our aim is cash operating profit break-even, after product development, in FY27.
- **We wrote down $13.1 million of intangible assets.** There was no cash impact. Our balance sheet now reflects what those assets are worth.

- **We developed new products.** Autonomous Coding and Autonomous Data Entry build on our existing capability, and we are now piloting them with existing customers.

New leadership this year

The most important decision of the review was appointing Gareth Pye as CEO. Gareth joined in July after 18 years at TechnologyOne, where he was CFO, strategy lead and product lead while that business grew from a domestic base into a global one. He has since brought our product heads into the executive team, so the people who build our products are in the room where priorities are set. I want to thank Marek Stepniak for his service and for his commitment to our team and our customers during his time as CEO.

David Crockett has joined as Chief Growth Officer. David has spent his career selling laboratory and diagnostic software, including at Magentus and Cirdan, and knows the RippleDown market well.

On the Board, Martin Bowles joined us this year and stands for election today. Martin was National CEO of Calvary Health Care and, before that, Secretary of the Australian Department of Health, so he brings the view of the healthcare leaders who buy and use our products.

Beamtree in an AI world

AI is making general software cheaper to build. That is a threat to any company whose only asset is its code. Like most companies, we use AI in our own teams, and we are building more, faster. But the real focus for us is how we build products for our healthcare customers. Our value there sits in three things that are hard to copy:

- **Clinical knowledge written as rules.** Every RippleDown rule is written by a named clinician, so each result comes with a reason, not a probability. Autonomous Coding and Autonomous Data Entry apply the same logic: AI reads the record and finds the evidence, our rules make the decision, and the customer checks the results before anything goes live. We will build on that technology in our new product development.
- **Our place in the workflow.** Our software runs inside hospitals and laboratories, on decades of coded data and peer benchmarking across 189 Health Round Table member hospitals in Australia and New Zealand. We are growing our presence in the UK through Evolve.
- **Trust, backed by regulation.** In health, an error can affect a patient's outcome or a hospital's funding. Health data and clinical coding are governed by regulatory frameworks in every market we serve, and Beamtree complies with them in Australia, New Zealand, the UK, Canada and Saudi Arabia.

Health systems need what AI offers because coding and laboratory workforces are short and costs are rising. But they need results that are accurate, explainable and auditable, and that is what we build. We are building quickly and will prove our results at customer sites. The team we have built gives us the means to do that. I want to end by thanking our shareholders, our customers and our fantastic team.

I will now pass over to Gareth to provide an update on the business achievements in FY26 and an overview of the outlook for Beamtree.

****

Beamtree®

FY26 Annual General Meeting

26th November 2026

Authorised for release by the Board of Directors

Important Notice and Disclaimer

The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, 26th November 2026.

This presentation may contain statements that are, or may be deemed to be, forward looking statements. Such statements can generally be identified by the use of words such as “believe”, “estimate”, “plan”, “target”, “project”, “anticipate”, “expect”, “intend”, “likely”, “may”, “will”, “could” or “should” and similar expressions. Indications of strategy, plans, objectives, targets, goals, future events or intentions are also forward-looking statements.

You should not place undue reliance on such forward-looking statements. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of BMT or any of its related entities which may cause actual results to differ materially from those expressed or implied in such statements.

No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation. Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

The information in the presentation is given for informational purposes only, is in summary form and does not purport to be complete. It is intended to be read by a professional analyst audience in conjunction with BMT’s other announcements to ASX. It is not intended to be relied upon as advice to current shareholders, investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor. No representation is made as to the accuracy, completeness or reliability of the presentation.

The views expressed in this presentation may contain information that has been derived from publicly available sources that have not been independently verified. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information. Market share information is based on management estimates except where explicitly identified.

To the maximum extent permitted by law, BMT and any person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation, any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

BMT is not obliged to, and does not represent that it will, update the presentation for future developments. All currency figures are in Australian dollars unless otherwise stated. Totals may not add up precisely due to rounding.



Copyright © Beamtree Holdings Limited – All Rights Reserved

AGM Agenda

1. Chair's Address



2. CEO Update



3. Order of Business



4. Q&A



5. Product Deep Dive – Knowledge Networks and Coding

Copyright © Beamtree Holdings Limited – All Rights Reserved

Beamtree®

2026 Annual General Meeting

CEO Address

Gareth Pye, Chief Executive Officer

26 November 2026



FY26 financial highlights

▲ 10%

$27.5m

Recurring revenue

up from 87%

94%

of revenue is recurring

▲ $1.0m on FY25

$0.3m

EBITDA

$0.4m

operating profit

+3%

operating costs

Low

single-digit churn

$13.1m

non-cash impairment

Reset

debt facility covenants

Copyright © Beamtree Holdings Limited – All Rights Reserved

Profit and loss

	FY25	FY26	FY26 Growth
Total Recurring Revenue	**25.0**	**27.5**	**10%**
Analytics	11.1	12.2	9%
Coding	5.8	7.0	21%
Diagnostics	7.5	7.9	6%
Clinical decision support & other	0.6	0.4	(31%)
Non-Recurring Revenue	**3.6**	**1.6**	**(54%)**
Total Revenue	**28.6**	**29.2**	**2%**
Expenses – people	(20.6)	(21.5)	5%
Expenses – non-people	(7.3)	(7.3)	0%
Total Operating Expenses	**(27.9)**	**(28.8)**	**3%**
Operating Profit	**0.7**	**0.4**	**(50%)**
Non-operational income & expense	(1.4)	(0.1)	(96%)
Goodwill impairment	-	(9.6)	100%
Software impairment	-	(3.6)	100%
Depreciation & amortisation	(5.5)	(5.1)	(7%)
Interest expense	(0.2)	(0.2)	41%
Income tax benefit/(expense)	0.2	(0.1)	(145%)
Net Profit/(Loss) after Income Tax	**(6.2)**	**(18.3)**	**(197%)**



Recurring revenue up 10%

Recurring revenue is 94% of total revenue, up from 87%.
Churn in low single digits.
Clinical Decision Support discontinued.



Operating expenses up 3% to $28.8m

People costs up 5%; non-people costs flat.



Goodwill impairment of $9.6m

Higher discount rates and more prudent long-term revenue forecasts. Non-cash.



Software impairment of $3.6m

Acquired software superseded by internally developed functionality.
Re-platformed and exited products written off.





Underlying ARR of $25.4m

Excludes discontinued products of $1.7m.

Figures in $m. Totals may not add due to rounding.

Recurring revenue by segment and geography





Copyright © Beamtree Holdings Limited – All Rights Reserved

Balance sheet and funding

	FY25	FY26
Current Assets		
Cash and cash equivalents	4.8	2.5
Trade and other receivables	4.7	5.2
Contract assets	0.1	0.3
Total Current Assets	**9.6**	**8.0**
Non-Current Assets		
Property, plant and equipment	0.2	0.2
Right-of-use assets	0.9	0.7
Intangible assets	41.8	27.8
Deferred tax assets	1.7	0.8
Total Non-Current Assets	**44.7**	**29.4**
Current Liabilities		
Trade and other payables	3.4	3.2
Borrowings	-	3.3
Contract liabilities	2.8	4.6
Other current liabilities	1.7	1.7
Total Current Liabilities	**7.8**	**12.8**
Non-Current Liabilities		
Lease liabilities	0.7	0.5
Borrowings	2.3	-
Other non-current liabilities	1.5	0.7
Total Non-Current Liabilities	**4.5**	**1.2**
Net Assets	**41.9**	**23.4**

Intangible assets of $27.8m

After $13.1m non-cash impairment
$3.7m invested in our products

Borrowings of $3.3m

Shown as current at 30 June 2026
BNZ covenant waiver received in August 2026
Covenants reset to align with the business

Liquidity of $5.5m

Cash of $2.5m and $3.0m undrawn facility
Operating cash flow of $0.9m

A focused portfolio across three operating segments



Analytics
(42% of revenue)

>10k

Unique benchmarks across ANZ in Health Roundtable



Coding
(30% of revenue)

73%

Of acute patient records in Australia processed by Beamtree



Diagnostics
(28% of revenue)

100m+

Cases interpreted through RippleDown each year

Copyright © Beamtree Holdings Limited – All Rights Reserved

FY27 priorities



Execution and focus

- Go-to-market:
  - Appointment of Chief Growth Officer
  - Re-engineer the sales process to drive outcomes and accountability
- Geographies:
  - Narrower geographic focus on solutions in each market
- Comprehensive product suite:
  - Leverage existing established products
  - Bring new ones to market, e.g. ACS and ADE
- Ongoing cost control

Copyright © Beamtree Holdings Limited – All Rights Reserved

FY27 priorities



Leverage our IP to bring value to our partners

- We have a strong foundation to leverage:
  - Domain expertise
  - Client trust
  - Data and AI depth
- Bringing these together allows us to create value for our stakeholders
- Improve awareness of Beamtree IP and capabilities

Copyright © Beamtree Holdings Limited – All Rights Reserved

FY27 priorities



Ai

- Ai in everything we do:
  - Productivity
  - Functional enhancements
  - Greater insights
- In our products: Ai with strong guard rails, built on decades of clinical data and domain expertise
- In how we build: Ai accelerating our own product development and lifting team productivity
- Customers get new capability sooner, at lower cost to build

Copyright © Beamtree Holdings Limited – All Rights Reserved

FY27 priorities


ARR growth

Focus & Execution

Leverage our IP

Ai


Grow ARR




* underlying ARR

Copyright © Beamtree Holdings Limited – All Rights Reserved


Login & Registration



01 Go to https://investor.automic.com.au/#/home



02 Under Meetings menu, click on "Join Meeting"




03 Follow the prompts to register your relevant holding(s)

For support call:

1300 816 159 (within Australia)
+61 2 8072 1479 (overseas)

Voting Instructions



01 Once registered and voting has opened, click on the "Voting" dropdown


02 Select either the "Full" or "Allocate" and then your voting direction for each resolution

03 Follow the prompts and "Submit Votes" before voting closes

For support call:

1300 816 159 (within Australia)
+61 2 8072 1479 (overseas)

Ask a Question



01 Click on the "Ask a Question" dropdown, then "Ask Question"

02 Choose Text Question or Verbal Question

03 Type your question then select the relevant resolution and holding/capacity. Once done click "Submit Question".

For support call:

1300 816 159 (within Australia)
+61 2 8072 1479 (overseas)

Voting Instructions



Proxies

Total Shares	295,342,591	100%
Proxies Received	54,776,181	18.54%

Financial Statements & Reports

“To receive and to consider the Annual Financial Report of the Company for the financial year ended 30 June 2026 together with the declaration of the Directors, the Directors’ Report, the Remuneration Report and the Auditor’s Report for that financial year.”

Resolutions



Resolution 1 – Adoption of Remuneration Report

To consider and, if thought fit, to pass the following as an ordinary resolution:

"That, for the purpose of Section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company's Annual Financial Report for the financial year ended 30 June 2026."

For	53,407,711	99.01%
Against	408,420	0.76%
Discretion	124,150	0.23%
Exclusions	735,900	
Abstain	157,771	

Resolution 2 – Re-election of Emma Gray as Director

To consider and, if thought fit, to pass the following as an ordinary resolution:

"That Emma Gray, a Director who retires by rotation in accordance with the Company's Constitution and ASX Listing Rule 14.5, and being eligible offers herself for re-election as a Director of the Company, be elected as a Director, effective immediately."

For	54,310,611	99.15%
Against	341,420	0.62%
Discretion	124,150	0.23%
Exclusions	0	
Abstain	57,771	

Resolution 3 – Election of Martin Bowles as Director

To consider and, if thought fit, to pass the following as an ordinary resolution:

"That Martin Bowles, a Director appointed as an additional Director and holding office until the next general meeting of the Company after his appointment in accordance with the Company's Constitution and ASX Listing Rule 14.4, be elected as a Director of the Company, effective immediately."

For	54,261,111	99.08%
Against	380,920	0.70%
Discretion	124,150	0.23%
Exclusions	0	
Abstain	67,771	

Resolution 4 – Approval of Issue of Shares to Emma Gray, Non-Executive Chair of the Company

To consider and, if thought fit, to pass the following as an ordinary resolution:

"That, for the purposes of section 208 of the Corporations Act, ASX Listing Rule 10.14 and for all other purposes, the Shareholders of the Company approve the issue and allotment of 1,200,974 fully paid ordinary shares under the Beamtree Holdings Employee Incentive Plan in lieu of interim Executive Chair's fees to Emma Gray (or her nominee), and otherwise on the terms and conditions set out in the Explanatory Statement which accompanies and forms part of this Notice of Meeting."

For	53,057,439	98.86%
Against	500,692	0.93%
Discretion	112,150	0.21%
Exclusions	735,900	
Abstain	427,771	

Resolution 5 – Approval of Issue of Shares to Michael Hill, Non-Executive Director of the Company

To consider and, if thought fit, to pass the following as an ordinary resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the Shareholders of the Company approve the issue and allotment of 351,426 fully paid ordinary shares under the Beamtree Holdings Employee Incentive Plan in lieu of Director's fees to Andy Hardy (or his nominee), and otherwise on the terms and conditions set out in the Explanatory Statement which accompanies and forms part of this Notice of Meeting."

For	53,057,439	98.86%
Against	500,692	0.93%
Discretion	112,150	0.21%
Exclusions	735,900	
Abstain	427,771	

Resolution 6 – Approval of Issue of Shares to Andy Hardy, Non-Executive Director of the Company

To consider and, if thought fit, to pass the following as an ordinary resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the Shareholders of the Company approve the issue and allotment of 351,426 fully paid ordinary shares under the Beamtree Holdings Employee Incentive Plan in lieu of Director's fees to Andy Hardy (or his nominee), and otherwise on the terms and conditions set out in the Explanatory Statement which accompanies and forms part of this Notice of Meeting."

For	53,057,439	98.86%
Against	500,692	0.93%
Discretion	112,150	0.21%
Exclusions	735,900	
Abstain	427,771	

Resolution 7 – Approval of Issue of Shares to Stuart MacDonald, Non-Executive Director of the Company

To consider and, if thought fit, to pass the following as a special resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the Shareholders of the Company approve the issue and allotment of 472,369 fully paid ordinary shares under the Beamtree Holdings Employee Incentive Plan in lieu of Director's fees to Stuart MacDonald (or his nominee), and otherwise on the terms and conditions set out in the Explanatory Statement which accompanies and forms part of this Notice of Meeting."

For	53,057,439	98.86%
Against	500,692	0.93%
Discretion	112,150	0.21%
Exclusions	735,900	
Abstain	427,771	

Resolution 8 – Approval of Issue of Shares to Martin Bowles, Non-Executive Director of the Company

To consider and, if thought fit, to pass the following as a special resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the Shareholders of the Company approve the issue and allotment of 638,320 fully paid ordinary shares under the Beamtree Holdings Employee Incentive Plan in lieu of Director's fees to Martin Bowles (or his nominee), and otherwise on the terms and conditions set out in the Explanatory Statement which accompanies and forms part of this Notice of Meeting."

For	53,047,439	98.86%
Against	500,692	0.93%
Discretion	112,150	0.21%
Exclusions	735,900	
Abstain	437,771	

Conducting of the Poll



Other Business



Thank You for Attending!

Better has no limit®